GHRP-6 agonizes the growth hormone secretagogue receptor, the same one ghrelin activates. Because ghrelin is the body's main hunger signal, GHRP-6 hunger is not an unexpected side effect. It is the predictable consequence of switching that receptor on.
What ghrelin is and what it does
Ghrelin was identified in 1999 as the endogenous ligand of a receptor that had been known before anyone knew what activated it. It is produced mainly in the stomach.
It has two established functions:
It stimulates growth hormone release by acting on the pituitary.
It is the body's main orexigenic signal, the hunger signal. Levels rise before meals and fall afterward. In a sense, it is the counterpart to the satiety signals handled by the GLP-1 class.
That a single molecule does both jobs is no accident. There is a physiological logic to pairing the "time to eat" signal with the "get ready to grow and repair" signal.
The shared receptor
GHRP-6 is a synthetic agonist of that same receptor. And that is the whole explanation of the compound: you cannot activate the ghrelin receptor and expect only half of its effects.
One consequence is worth stating plainly. GHRP-6 hunger is not a manufacturing defect or an impurity. It is what the receptor does when it is activated. Presenting it as an avoidable side effect means the mechanism was never understood.
Why the appetite response varies so much
In practice, the size of the effect on hunger differs widely from person to person. The factors the literature associates with that variability:
- Prior nutritional status. Endogenous ghrelin tone differs with energy balance.
- Receptor density and sensitivity, which vary between individuals.
- Timing relative to meals. The response is not the same fasted as after eating.
- Desensitization. With repeated administration, the appetite response tends to fade before the GH response does.
That last observation is interesting and not widely known: the two responses from the same receptor do not desensitize at the same rate.
GHRP-6 versus GHRP-2 and ipamorelin
| GHRP-6 | GHRP-2 | Ipamorelin | |
|---|---|---|---|
| GH stimulus | Marked | Marked | Marked |
| Appetite | Very marked | Moderate | Minimal |
| Cortisol / ACTH | Appreciable | Appreciable | Minimal |
| Prolactin | Appreciable | Appreciable | Minimal |
All three act on the same receptor and produce different profiles. The explanation the literature works with is functional selectivity: different agonists of the same receptor can preferentially activate some signaling pathways over others.
This is a recognized phenomenon in the pharmacology of G protein-coupled receptors. And it should be said that the mechanistic detail of why GHRP-6 is so orexigenic while ipamorelin barely is has not been fully resolved. The contrast from the other side is in the article on ipamorelin.
Effects on cortisol and prolactin
GHRP-6 appreciably raises ACTH (and with it cortisol) as well as prolactin.
Why that matters:
Cortisol has catabolic effects on muscle tissue and takes part in regulating blood glucose, blood pressure, and the inflammatory response. A sustained elevation is not a minor detail.
Prolactin elevated chronically can interfere with the reproductive axis.
In acute administration studies, both elevations are moderate and transient. What happens with repeated administration over months is far less well characterized, and that is a relevant gap.
The context where that effect is useful and the one where it is not
Here is the honest use of everything above.
The orexigenic effect is neither intrinsically good nor bad. It depends entirely on the goal. Research on ghrelin agonists exists precisely in settings where stimulating appetite is the therapeutic aim (cachexia, disease-associated anorexia), and that is a legitimate field of study.
In a setting where the goal runs the other way, the same effect is an obstacle.
What this article deliberately does not do is tell anyone which compound to use for their goal. It describes what each one does. The decision is a different matter, and it belongs to a professional.
Batch analytical data are in its technical sheet, and the overview of the two families is in the GH axis pillar.
What the evidence does not settle
The effects of repeated administration on cortisol and prolactin across months.
The real magnitude of desensitization for each of the receptor's two responses.
Any functional outcome. What exists are hormone secretion studies, that is, markers.
Predictors of individual response: none has been validated.
Frequently asked questions
Why does GHRP-6 cause so much hunger?
Because it activates the ghrelin receptor, the body's main hunger signal. GHRP-6 hunger is not an avoidable side effect. It is what that receptor does.
Does the hunger fade over time?
The literature describes attenuation of the appetite response with repeated administration, at a different rate from the GH response. The magnitude varies widely between people.
Is it worse than ipamorelin?
This is not a question of better or worse, but of profile. GHRP-6 produces more appetite and a larger rise in cortisol and prolactin; ipamorelin is more selective. Which one fits depends on the context, and that assessment belongs to a professional.
Is the rise in cortisol a concern?
In acute administration studies it is moderate and transient. What happens with repeated administration over months is poorly characterized, and that absence of data is itself relevant information.
References
- Kojima M, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature, 1999;402:656–660. DOI: 10.1038/45230
- Bowers CY. Growth hormone-releasing peptide (GHRP). Cellular and Molecular Life Sciences, 1998;54(12):1316–1329. DOI: 10.1007/s000180050252
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998;139(5):552–561. DOI: 10.1530/eje.0.1390552
- Müller TD, et al. Ghrelin. Molecular Metabolism, 2015;4(6):437–460. DOI: 10.1016/j.molmet.2015.03.005
Written by the Bionic Editorial Team. Last reviewed: August 2026.
How we work: our editorial policy and source hierarchy.
This content is strictly educational and does not constitute medical advice, diagnosis or a therapeutic recommendation. The compounds mentioned are research products (Research Use Only) and are not approved by INVIMA, FDA, EMA or ANSM for therapeutic use in humans. Any health-related decision should be made with a licensed medical professional.